Johanna S. Ungerstedt

Plasma proteome screen of individuals with elevated blood counts to identify diagnostic signatures and biomarkers inherent to patients with myeloproliferative neoplasms

Xiangfu Zhong, Ingrid E. J. Lundahl, Axel Rosell, Roza Chaireti et autres

Abstract Background The Philadelphia negative myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF), are characterized by myeloid cell proliferation, thrombosis and inflammation. Suspicion of MPN arises from increased blood count in one or more lineages; however, …

se (code pays fourni par la source)

Real-world investigation of germline predisposition to myelodysplastic syndromes

Anna Tranberg, Maria Creignou, Teresa Mortera-Blanco, Elsa Bernard et autres

Follow-up of potential germline variants revealed by diagnostic targeted sequencing (TS) for myelodysplastic syndromes (MDS) has been proposed by clinical guidelines. However, their feasibility and clinical yield in routine MDS practice remain uncertain. We evaluated real-world applicability of systematic germline follow-up in …

se, fr, es, us (code pays fourni par la source)

Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study

Frank Siebenhaar, Sigurd Broesby‐Olsen, Mariana Castells, Tracy I. George et autres

BACKGROUND: Indolent systemic mastocytosis (ISM), a clonal mast cell disease driven by the KIT D816V mutation, can often cause debilitating dermatologic symptoms. OBJECTIVE: Assess improvement of ISM-related skin manifestations after treatment with avapritinib, a highly selective KIT D816V inhibitor, vs placebo in …

de, dk, us, fr, es, no, nl, gb, ca, be, se, ch (code pays fourni par la source)

Figure S5 from HDAC Inhibition Triggers Release of RNA Polymerase II from Promoter-Proximal Pausing in Healthy Blood Progenitors and Primary Acute Myeloid Leukemia Myeloblasts

Yanzi Xing, Alexander Pfab, George Hunt, Kajsa Ax et autres

Figure S5 shows redistribution of BRD4, and stronger acetylation and BRD4 at upregulated genes compared to other highly paused genes

Figure S4 from HDAC Inhibition Triggers Release of RNA Polymerase II from Promoter-Proximal Pausing in Healthy Blood Progenitors and Primary Acute Myeloid Leukemia Myeloblasts

Yanzi Xing, Alexander Pfab, George Hunt, Kajsa Ax et autres

Figure S4 shows histone acetylation changes and Pol II pausing after HDAC inhibition

Table S1 from HDAC Inhibition Triggers Release of RNA Polymerase II from Promoter-Proximal Pausing in Healthy Blood Progenitors and Primary Acute Myeloid Leukemia Myeloblasts

Yanzi Xing, Alexander Pfab, George Hunt, Kajsa Ax et autres

Table S1 shows differentially expressed genes between healthy and AML samples based on PRO-seq and CUT&Tag, as well as GO terms

Figure S2 from HDAC Inhibition Triggers Release of RNA Polymerase II from Promoter-Proximal Pausing in Healthy Blood Progenitors and Primary Acute Myeloid Leukemia Myeloblasts

Yanzi Xing, Alexander Pfab, George Hunt, Kajsa Ax et autres

Figure S2 shows the difference in H3K27ac between healthy CD34+ progenitors and AML samples

Table S2 from HDAC Inhibition Triggers Release of RNA Polymerase II from Promoter-Proximal Pausing in Healthy Blood Progenitors and Primary Acute Myeloid Leukemia Myeloblasts

Yanzi Xing, Alexander Pfab, George Hunt, Kajsa Ax et autres

Table S2 shows differentially expressed genes between DMSO control and SAHA treatment based on PRO-seq

Data from HDAC Inhibition Triggers Release of RNA Polymerase II from Promoter-Proximal Pausing in Healthy Blood Progenitors and Primary Acute Myeloid Leukemia Myeloblasts

Yanzi Xing, Alexander Pfab, George Hunt, Kajsa Ax et autres

Abstract Histone deacetylase (HDAC) inhibitors have been considered as anti-leukemic agents but have shown poor efficacy in clinical trials. In this study, we investigated the immediate transcriptional response to the HDAC inhibitor SAHA (vorinostat) in healthy CD34+ blood stem/progenitor cells and myeloblasts …

Table S3 from HDAC Inhibition Triggers Release of RNA Polymerase II from Promoter-Proximal Pausing in Healthy Blood Progenitors and Primary Acute Myeloid Leukemia Myeloblasts

Yanzi Xing, Alexander Pfab, George Hunt, Kajsa Ax et autres

Table S3 shows CUT&Tag histone acetylation data

Figure S1 from HDAC Inhibition Triggers Release of RNA Polymerase II from Promoter-Proximal Pausing in Healthy Blood Progenitors and Primary Acute Myeloid Leukemia Myeloblasts

Yanzi Xing, Alexander Pfab, George Hunt, Kajsa Ax et autres

Figure S1 shows differences in gene expression and Pol II signal between healthy CD34+ progenitors and AML samples

Figure S3 from HDAC Inhibition Triggers Release of RNA Polymerase II from Promoter-Proximal Pausing in Healthy Blood Progenitors and Primary Acute Myeloid Leukemia Myeloblasts

Yanzi Xing, Alexander Pfab, George Hunt, Kajsa Ax et autres

Figure S3 shows that HDAC inhibition for 10 min increases transcription for the first 25 kb